Pharmacokinetics of IV Pantoprazole in Pediatric Patients

  title={Pharmacokinetics of IV Pantoprazole in Pediatric Patients},
  author={G. Ferron and S. Schexnayder and J. Marshall and J. L. Blumer and A. Rodarte and M. Abell and B. Mako and P. Fraga and J. Getsy and J. Paul},
  journal={Clinical Pharmacology \& Therapeutics},
Clinical Pharmacology & Therapeutics (2003) 73, P37–P37; doi: 

Topics from this paper

Pantoprazole in pediatric gastroesophageal reflux disease
Additional pharmacokinetic and clinical data are needed with this PPI, which may prove the suitability of its use in children and be used to seek pediatric labeling. Expand
Review of pantoprazole in pediatrics
P pantoprazole was efficacious in resolving gastroesophageal reflux symptoms partially or completely in 1–16-year-old subjects and in healing erosive esophagitis, however, it was not effective in treating infants under 1 year of age with symptoms suggestive of GERD and because of unavailability of formulation appropriate for children younger than 5 years; it is not approved for use under this age. Expand
Pharmacokinetics of Proton Pump Inhibitors in Children
Because a pharmacokinetic/pharmacodynamic relationship exists for PPIs, the significant interindividual variability in their disposition may partly explain the wide range of therapeutic doses used in children. Expand
Single‐Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents
The pharmacokinetic values were similar in patients from ages 2 to 16 years and to those previously obtained in adults and Statistically significant differences were observed for dose‐normalized pantoprazole area under the plasma concentration‐time curve when compared between CYP2C19 extensive metabolizers with 1 versus 2 functional alleles. Expand
Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients.
Pantoprazole clearance was significantly influenced by developmental changes and by the presence of systemic inflammatory syndrome, hepatic dysfunction and CYP2C19 inhibitors, which provided important information for physicians regarding selection of a starting dose and dosing regimens of pantoprazoles for paediatric intensive care patients. Expand
Drug Evaluation Review of pantoprazole in pediatrics
  • 2011
Gastroesophageal reflux (GER) is occasionally experienced by almost everyone post-prandially and is a normal physiologic phenomenon under such circumstances. However, when it occurs frequentlyExpand
Multicenter, Randomized, Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) with Gastroesophageal Reflux Disease (GERD)
Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents and safety was comparable between the 2 groups. Expand
Ontogeny of drug metabolizing enzymes in the neonate.
An appreciation of the impact of ontogeny on the expression and functional activity of the major drug-metabolizing enzymes enables the practicing clinician to predict the ultimate consequence of drug administration in the neonate to help guide optimal drug therapy. Expand
Multicenter, Randomized, Double-Blind Study Comparing 10, 20 and 40 mg Pantoprazole in Children (5-11 Years) With Symptomatic Gastroesophageal Reflux Disease
Pantoprazole (20 and 40 mg) is effective in reducing endoscopically proven GERD symptoms in children and significantly reduced symptoms as early as 1 week. Expand
Nouvelle méthode de revue d’utilisation des médicaments : application au pantoprazole intraveineux en réanimation pédiatrique
Cette etude illustre une premiere demarche de revue d’utilisation rapide de medicaments en etablissement of sante, which permet une evaluation structuree dans un temps limite dans cet article. Expand